-
Legend Biotech Gains Access to MaxCyte’s Cell Engineering Tech with New License Agreement
•
China’s Legend Biotech Corporation (NASDAQ: LEGN) has entered into a strategic platform license (SPL) agreement with US-based cell-engineering company MaxCyte Inc., (NASDAQ: MXCT). The agreement grants Legend Bio a non-exclusive worldwide license to leverage MaxCyte’s Flow Electroporation technology and ExPERT platform. This access will facilitate Legend Bio’s research, clinical development,…
-
Lion TCR Partners with MaxCyte to Develop mRNA-Based TCR-T Therapies for Solid Tumors and Viral Diseases
•
Lion TCR, a Singapore-based clinical-stage biotechnology company with backing from Chinese investors, has entered into a partnership with U.S. firm MaxCyte Inc. to harness mRNA technology for the development of TCR-T therapies. These therapies are aimed at treating solid tumors and virus-related diseases. The collaboration will enable Lion to utilize…
